Reply #34: Here is another great example of the problem [View All]

[BakedAtAMileHigh]

...this took about 5 seconds to Google. There are literally thousands of other examples out there.

http://industry.bnet.com/pharma/10003923/doc-who-urged-antipsychotics-for-3-year-olds-funded-by-jj-az-and-shire/?tag=content;selector-perfector

UPDATED: Doc Who Urged Antipsychotics for 3-Year-Olds Funded by J&J, AZ and Shire

By Jim Edwards | Aug 28, 2009

A doctor who wrote in an academic journal that preschoolers may suffer from depression and could be good candidates for atypical antipsychotics received funding from three drug companies that make mental health medicines.

Dr. Joan Luby, a professor of child psychiatry at the Washington University School of Medicine in St. Louis, wrote that children as young as three years old may suffer from bipolar disorder, and that there are “promising findings for the use of atypical antipsychotic agents and mood stabilizers, both singly and in combination” in the very young. Atypical antipsychotics are not FDA-approved for such use.

Her article, in a 2009 journal titled Child and Adolescent Psychiatric Clinics of North America, does not disclose that in the past Luby’s work has been funded by Janssen (the unit of Johnson & Johnson that markets Risperdal), or that she has given talks sponsored by AstraZeneca (maker of Seroquel), and has been a consultant for Shire (maker of Adderall XR and Vyvanse).